Cellmat Therapeutics Submits Objection to Delisting Notice
[Asia Economy Reporter Kim Young-won] Cellmat Therapeutics announced on the 8th that it has submitted an objection to the delisting. Cellmat Therapeutics also received a refusal of audit opinion from the auditor on its financial statements for the 2020 fiscal year.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- One in 77 Koreans Exposed to Drugs... Enough Money for 6,600 Luxury Gangnam Apartments Circulates in Drug Market [ChwiYakGukga] ⑩
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "The Korea Exchange will hold a Securities Market Listing Disclosure Committee meeting to conduct a combined review of the delisting reasons related to the audit opinions for the 2020 and 2021 fiscal years and will decide on the delisting status of Cellmat Therapeutics."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
